Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0037 | Desipramine

Molecular Formula C18H22N2
Molecular Weight 266.4
Structure
State solid
Route of elimination Desipramine is metabolized in the liver, and approximately 70% is excreted in the urine.
Protein binding 73-92% bound to plasma proteins
Half life 7-60+ hours; 70% eliminated renally
Absorption Desipramine hydrochloride is rapidly and almost completely absorbed from the gastrointestinal tract. It undergoes extensive first-pass metabolism. Peak plasma concentrations are attained 4 - 6 hours following oral administration.
Trade names Norpramin, Pertofrane
Description dibenzazepine-derivative tricyclic antidepressant (TCA); inhibitors of serotonin and norepinephrine reuptake

N

N06AA01 Desipramine


[N06AA] Non-selective monoamine reuptake inhibitors


[N06A] ANTIDEPRESSANTS


[N06] PSYCHOANALEPTICS


[N] Nervous system

Toxicity Dose Time Species Model Method Action Positive criterion Reference
ATP LEVEL 197
ROS PRODUCTION 197

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 3 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H302 (66.67%): Harmful if swallowed [Warning Acute toxicity, oral]


H336 (66.67%): May cause drowsiness or dizziness [Warning Specific target organ toxicity, single exposure


Narcotic effects]


H370 (66.67%): Causes damage to organs [Danger Specific target organ toxicity, single exposure]


H400 (33.33%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P260, P261, P264, P270, P271, P273, P301+P312, P304+P340, P307+P311, P312, P321, P330, P391, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
rat LD50 intravenous 29mg/kg (29mg/kg) Archives Internationales de Pharmacodynamie et de Therapie. Vol. 148, Pg. 560, 1964.
women TDLo oral 14mg/kg/1W-I (14mg/kg) kidney, ureter, and bladder: urine volume decreased Journal of Clinical Psychiatry. Vol. 44, Pg. 153, 1983.
women TDLo oral 36mg/kg/6D-I (36mg/kg) Journal of Clinical Psychiatry. Vol. 53, Pg. 160, 1992.
guinea pig LDLo intravenous 55mg/kg (55mg/kg) cardiac: other changes Therapie. Vol. 20, Pg. 67, 1965.
mouse LD50 intraperitoneal 85mg/kg (85mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 1727, 1971.
women TDLo oral 45mg/kg (45mg/kg) Annals of Pharmacotherpy. Vol. 27, Pg. 572, 1993.
mouse LD50 oral 315mg/kg (315mg/kg) "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 70, 1972.
rat LD50 intraperitoneal 48mg/kg (48mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1561, 1970.
man TDLo oral 490ug/kg (0.49mg/kg) behavioral: sleep Journal of Clinical Psychiatry. Vol. 47, Pg. 210, 1986.
women TDLo oral 59mg/kg (59mg/kg) Mayo Clinic Proceedings. Vol. 59, Pg. 574, 1984.
rat LD50 intraperitoneal 55mg/kg (55mg/kg) "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 70, 1972.
dog LD50 intravenous 25mg/kg (25mg/kg) "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 70, 1972.
mouse LD50 intravenous 37mg/kg (37mg/kg) International Journal of Neuropharmacology. Vol. 4, Pg. 111, 1965.
man TDLo oral 1643mg/kg/1Y- (1643mg/kg) Clinical Pediatrics Vol. 31, Pg. 635, 1992.
women TDLo oral 70mg/kg/4W-I (70mg/kg) American Journal of Psychiatry. Vol. 142, Pg. 386, 1985.
mouse LD50 intraperitoneal 880mg/kg (880mg/kg) behavioral: changes in motor activity (specific assay) Dissertationes Pharmaceuticae et Pharmacologicae. Vol. 18, Pg. 19, 1966.
rabbit LD50 intravenous 12mg/kg (12mg/kg) Archives Internationales de Pharmacodynamie et de Therapie. Vol. 148, Pg. 560, 1964.
women TDLo oral 14mg/kg/1W-I (14mg/kg) Journal of Clinical Psychiatry. Vol. 44, Pg. 153, 1983.
mouse LD50 intraperitoneal 88mg/kg (88mg/kg) "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 70, 1972.
man TDLo oral 5mg/kg/5D-I (5mg/kg) American Journal of Psychiatry. Vol. 142, Pg. 386, 1985.
rat LD50 intravenous 19mg/kg (19mg/kg) "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 70, 1972.
women LDLo oral 30mg/kg (30mg/kg) "Toxicology of Drugs and Chemicals," Deichmann, W.B., New York, Academic Press, Inc., 1969Vol. -, Pg. 201, 1969.
mouse LD50 subcutaneous 214mg/kg (214mg/kg) Farmaco, Edizione Pratica. Vol. 25, Pg. 519, 1970.
rat LD50 oral 871mg/kg (871mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 33, Pg. 1411, 1983.
child LDLo oral 125mg/kg (125mg/kg) Psychopharmacologia Vol. 10, Pg. 431, 1967.
rat LD50 oral 375mg/kg (375mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 19, Pg. 1617, 1969.
rabbit LD50 oral 1gm/kg (1000mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 19, Pg. 1617, 1969.
mouse LD50 oral 448mg/kg (448mg/kg) Japanese Journal of Pharmacology. Vol. 21, Pg. 47, 1971.
rat LD50 subcutaneous 183mg/kg (183mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1561, 1970.
human LDLo oral 30mg/kg (30mg/kg) Deutsche Medizinische Wochenschrift. Vol. 93, Pg. 117, 1968.
mouse LD50 intravenous 22mg/kg (22mg/kg) Acta Pharmaceutica Suecica. Vol. 12, Pg. 173, 1975.

  • Bipolar disorder

  • Bipolar I disorder

  • Depression

  • Dysthymic disorder

  • Orthostatic hypotension

  • Psychotic disorder

    • (3-(10H,11H-Dibenzo[b,f]azepin-5-yl)propyl)methylamine (3-{2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)(methyl)amine 050D475
    10, 11-Dihydro-N-methyl-5H-dibez[b,f]azepine-5-propanamine 10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE
    3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methyl-1-propanamine # 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl);-N-methylpropan-1-amine 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine hydrochloride
    3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methyl-propan-1-amine 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine 5-(3-methylaminopropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine
    5-(gamma-Methylaminopropyl)iminodibenzyl 50-47-5 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(methylamino)propyl)-
    5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N-methyl- 5H-Dibenz[b,f]azepine, 10,11-dihydro-5-[3-(methylamino)propyl]- 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N-methyl-
    5H-Dibenzo[b, f]azepine, N-(3-methylaminopropyl)-, 10,11-Dihydro 6943AB AB00053450
    AB00053450_14 AC-15977 AKOS001681456
    ALBB-025959 API0009063 AX8123821
    BDBM35229 BPBio1_000447 BRD-K60762818-003-15-3
    BRN 1432747 BSPBio_000405 BSPBio_002137
    C06943 CAS-58-28-6 CCG-118231
    CCRIS 7091 CHEBI:47781 CHEMBL72
    D07791 DB01151 DMI (pharmaceutical)
    DMI 50475 DTXSID6022896 Demethylimipramine
    Desimipramine Desimpramine Desipramin
    Desipramina Desipramina [INN-Spanish] Desipramine (D4)
    Desipramine (INN) Desipramine [INN:BAN] Desipraminum [INN-Latin]
    Desmethylimipramine Dezipramine Dimethylimipramine
    DivK1c_000190 EINECS 200-040-0 GTPL2399
    HCYAFALTSJYZDH-UHFFFAOYSA-N HMS3430H03 HMS3742I19
    HSDB 3052 IDI1_000190 Imipramine, demethyl-
    KBio1_000190 KBio2_000921 KBio2_003489
    KBio2_006057 KBio3_001357 KBioGR_000928
    KBioSS_000921 L001089 LS-60421
    Lopac-D-3900 Lopac0_000358 MCULE-5904286906
    Methylaminopropyliminodibenzyl Monodemethylimipramine N-(3-Methylaminopropyl)iminobibenzyl
    NCGC00015340-01 NCGC00015340-02 NCGC00015340-03
    NCGC00015340-04 NCGC00015340-05 NCGC00015340-06
    NCGC00015340-07 NCGC00015340-08 NCGC00015340-09
    NCGC00015340-10 NCGC00015340-11 NCGC00015340-13
    NCGC00024375-04 NINDS_000190 Norimipramine
    Norpramine Pertofran (Salt/Mix) Pertofrane (Salt/Mix)
    Pertrofane Prestwick0_000343 Prestwick1_000343
    Prestwick2_000343 Prestwick3_000343 Q423288
    R1868 SBB002569 SBI-0050346.P004
    SCHEMBL34384 SPBio_000042 SPBio_002326
    ST052019 STK735144 Sertofran
    Spectrum2_000091 Spectrum3_000379 Spectrum4_000314
    Spectrum5_000833 Spectrum_000441 TG537D343B
    Treyzafagit UNII-TG537D343B ZINC1530611
    ZX-AN024471 [3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl]methylamine [3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl]methylamine hydrochloride
    desipramine desipraminum

    DrugBank Name Desipramine
    DrugBank DB01151
    CAS Number 300-87-8, 50-47-5, 58-28-6
    PubChem Compound 2995
    KEGG Compound ID C06943
    KEGG Drug D07791
    PubChem.Substance 46504624
    ChEBI 47781
    PharmGKB PA449233
    ChemSpider 2888
    BindingDB 35229.0
    TTD DAP001151
    Wikipedia Desipramine
    HET DSM
    DPD 10024|11181

    1. Vuda et al. (2016)